Related Experiment Video

Updated: Aug 6, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue

Andrea Bartok1, Sabine Steiner, Daniela Seidinger

  • 12nd Department of Medicine, Division of Angiology, Medical University of Vienna, Vienna, Austria, Währinger Gürtel 18-20, A-1090 Wien, Austria.

Thrombosis Research
|March 29, 2005
PubMed

Insights

Atorvastatin therapy after coronary angioplasty reduced thrombin generation in vivo. This effect occurred independently of changes in soluble tissue factor (sTF) or tissue factor pathway inhibitor (TFPI).

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Thrombosis Research

Background:

  • Statins are known to inhibit cellular tissue factor (TF) in vitro.
  • The in vivo effects of atorvastatin on the TF-pathway and thrombin generation post-PCI require further investigation.

Purpose of the Study:

  • To investigate the impact of atorvastatin on the tissue factor (TF) pathway and thrombin generation following percutaneous coronary intervention (PCI) and stenting.
  • To assess the influence of different doses of atorvastatin on these markers in patients with coronary artery disease (CAD).

Main Methods:

  • A randomized trial involving 30 CAD patients, divided into three groups: no statin, 10 mg atorvastatin, and 80 mg atorvastatin daily for 6 months post-PCI.
  • Blood samples were collected at baseline, 6 weeks, and 6 months to measure soluble TF (sTF), free TFPI, and prothrombin fragment F1.2 (a marker of thrombin generation).

Main Results:

  • A significant correlation between sTF and thrombin generation (F1.2) at baseline was lost after 6 weeks and 6 months of atorvastatin therapy.
  • Both low-dose (10 mg) and high-dose (80 mg) atorvastatin significantly reduced F1.2 levels after 6 months compared to the control group.
  • No significant changes in sTF or free TFPI levels were observed with atorvastatin therapy.

Conclusions:

  • Atorvastatin therapy effectively reduces in vivo thrombin generation six months after PCI.
  • The observed reduction in thrombin generation is independent of significant changes in sTF or free TFPI levels.
Abstract

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...